following an abbreviated submission:
guselkumab (Tremfya®) is accepted for use within NHSScotland.
Indication under review: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
Guselkumab offers an additional treatment choice in the therapeutic class of interleukin inhibitors in this setting.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice353KB (PDF)
Medicine details
- Medicine name:
- guselkumab (Tremfya)
- SMC ID:
- SMC2850
- Indication:
For the treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 November 2025